Screening of potent drug inhibitors against SARS-CoV-2 RNA polymerase: an in silico approach.

ABSTRACT: COVID-19 has emerged as a rapidly escalating serious global health issue, affecting every section of population in a detrimental way. Present situation invigorated researchers to look for potent targets, development as well as repurposing of conventional therapeutic drugs. NSP12, a RNA polymerase, is key player in viral RNA replication and, hence, viral multiplication. In our study, we have screened a battery of FDA-approved drugs against SARS-CoV-2 RNA polymerase using in silico molecular docking approach. Identification of potent inhibitors against SARS-CoV-2 NSP12 (RNA polymerase) were screeened from FDA approved drugs by virtual screening for therapeutic applications in treatment of COVID-19. In this study, virtual screening of 1749 antiviral drugs was executed using Auto

SUBMITTER: Singh SK 

PROVIDER: S-EPMC7826501 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature